The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents

Critical Reviews in Oncology/Hematology

Volumn 56, Issue 1 SPEC. ISS., 2005, Pages 169-178

  Kwon, John H ^a   Farrell, Richard J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Center for Inflammatory Bowel Disease   (United States)

Author keywords

Immunomodulators; Inflammatory bowel disease; Lymphoma; Myelosuppression

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER RISK; DRUG MONITORING; ENTERITIS; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOMODULATION; INFECTION; LIVER GRAFT; LYMPHOMA; NONHODGKIN LYMPHOMA; PATIENT MONITORING; PSORIASIS; REED STERNBERG CELL; REVIEW; RHEUMATOID ARTHRITIS;

CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; LYMPHOMA;

EID: 24644495220     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2005.02.004     Document Type: Review

References (82)

1. F. Shanahan Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics Gastroenterology 120 3 2001 622 635
2. D.K. Podolsky Inflammatory bowel disease N Engl J Med 347 6 2002 417 429
3. D.H. Present, B.I. Korelitz, N. Wisch, J.L. Glass, D.B. Sachar, and B.S. Pasternack Treatment of Crohn's disease with 6-mercaptopurine: a long-term, randomized double-blind study N Engl J Med 302 1980 981 987
4. Y. Bouhnik, M. Lemann, and J.Y. Mary Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine Lancet 347 8996 1996 215 219
5. S. Lichtiger, D.H. Present, and A. Kornbluth Cyclosporine in severe ulcerative colitis refractory to steroid therapy N Engl J Med 330 1994 1841 1845
6. A. Kornbluth, D.H. Present, S. Lichtiger, and S.B. Hanauer Cyclosporin for severe ulcerative colitis: a users guide Am J Gastroenterol 92 1997 1424 1428
7. G. D'Haens, L. Lemmens, and K. Geboes Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis Gastroenterology 120 2001 1323 1329
8. R. Oren, N. Arber, and S. Odes Methotrexate in chronic active ulcerative colitis: a double-blind, randomized Israeli multicenter trial Gastroenterology 110 1996 1416 1421
9. B.G. Feagan, R.N. Fedorak, and E.J. Irvine A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 342 2000 1627 1632
10. B.G. Feagan, J. Rochon, and R.N. Fedorak Methotrexate for the treatment of Crohn's disease. North American Crohn's Study Group Investigators N Engl J Med 332 1995 292 297
11. D.H. Present, P. Rutgeerts, and S. Targan Infliximab for the treatment of fistulas in patients with Crohn's disease N Engl J Med 340 1999 1398 1405
12. S.B. Hanauer, B.G. Feagan, and G.R. Lichtenstein Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 9317 2002 1541 1549
13. B.E. Sands, F.H. Anderson, and C.N. Bernstein Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 9 2004 876 885
14. The state of the art in the management of inflammatory bowel disease. Clinician 2002;20(3):1-19.
15. R. Hoover, and J.F. Fraumeni Jr. Risk of cancer in renal-transplant recipients Lancet 2 7820 1973 55 57
16. L.J. Kinlen Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment Am J Med 78 1A 1985 44 49
17. K.G. Moder, A. Tefferi, M.D. Cohen, D.M. Menke, and H.S. Luthra Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: a retrospective study Am J Med 99 3 1995 276 281
18. G. Opelz, and R. Henderson Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients Lancet 342 8886-8887 1993 1514 1516
19. G. Ciancio, A.P. Siquijor, and G.W. Burke Post-transplant lymphoproliferative disease in kidney transplant patients in the new immunosuppressive era Clin Transplant 11 3 1997 243 249
20. J. Bargen Chronic ulcerative colitis associated with malignant disease Arch Surg 93 1928 1307 1311
21. P.M. Perosio, J.J. Brooks, S.H. Saul, and D.G. Haller Primary intestinal lymphoma in Crohn's disease: minute tumor with a fatal outcome Am J Gastroenterol 87 7 1992 894 898
22. N.A. Shepherd, P.A. Hall, and G.T. Williams Primary malignant lymphoma of the large intestine complicating chronic inflammatory bowel disease Histopathology 15 4 1989 325 337
23. M.D. Kelly, M. Stuart, M. Tschuchnigg, J. Turner, and T. Tydd Primary intestinal Hodgkin's disease complicating ileal Crohn's disease Aust N Z J Surg 67 7 1997 485 489
24. H.B. Friedman, G.M. Silver, and C.H. Brown Lymphoma of the colon simulating ulcerative colitis. Report of four cases Am J Dig Dis 13 10 1968 910 917
25. A.J. Greenstein, G.E. Mullin, and J.A. Strauchen Lymphoma in inflammatory bowel disease Cancer 69 5 1992 1119 1123
26. M.E. Robert, F.C. Kuo, J.A. Longtine, J.L. Sklar, T. Schrock, and N. Weidner Diffuse colonic mantle cell lymphoma in a patient with presumed ulcerative colitis: detection of a precursor monoclonal lymphoid population using polymerase chain reaction and immunohistochemistry Am J Surg Pathol 20 8 1996 1024 1031
27. A.B. Weir, M.C. Poon, J.F. Groarke, and J.A. Wilkerson Lymphoma simulating Crohn's colitis Dig Dis Sci 25 1 1980 69 72
28. S.N. Glick, S.K. Teplick, L.R. Goodman, H.R. Clearfield, and J.D. Shanser Development of lymphoma in patients with Crohn disease Radiology 153 2 1984 337 339
29. P.G. Persson, P. Karlen, and O. Bernell Crohn's disease and cancer: a population-based cohort study Gastroenterology 107 6 1994 1675 1679
30. D. Palli, G. Trallori, and S. Bagnoli Hodgkin's disease risk is increased in patients with ulcerative colitis Gastroenterology 119 3 2000 647 653
31. L. Mellemkjaer, J.H. Olsen, M. Frisch, C. Johansen, G. Gridley, and J.K. McLaughlin Cancer in patients with ulcerative colitis Int J Cancer 60 3 1995 330 333
32. E.V. Loftus Jr., W.J. Tremaine, T.M. Habermann, W.S. Harmsen, A.R. Zinsmeister, and W.J. Sandborn Risk of lymphoma in inflammatory bowel disease Am J Gastroenterol 95 9 2000 2308 2312
33. J.D. Lewis, W.B. Bilker, C. Brensinger, J.J. Deren, D.J. Vaughn, and B.L. Strom Inflammatory bowel disease is not associated with an increased risk of lymphoma Gastroenterology 121 5 2001 1080 1087
34. T. Jess, K.V. Winther, P. Munkholm, E. Langholz, and V. Binder Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark Aliment Pharmacol Ther 19 3 2004 287 293
35. P. Karlen, R. Lofberg, O. Brostrom, C.E. Leijonmarck, G. Hellers, and P.G. Persson Increased risk of cancer in ulcerative colitis: a population-based cohort study Am J Gastroenterol 94 4 1999 1047 1052
36. A. Ekbom, C. Helmick, M. Zack, and H.O. Adami Extracolonic malignancies in inflammatory bowel disease Cancer 67 7 1991 2015 2019
37. C.N. Bernstein, J.F. Blanchard, E. Kliewer, and A. Wajda Cancer risk in patients with inflammatory bowel disease: a population-based study Cancer 91 4 2001 854 862
38. R.J. Farrell, Y. Ang, and P. Kileen Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low Gut 47 4 2000 514 519
39. A.G. Fraser, T.R. Orchard, E.M. Robinson, and D.P. Jewell Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine Aliment Pharmacol Ther 16 7 2002 1225 1232
40. A.J. Greenstein, R. Gennuso, and D.B. Sachar Extraintestinal cancers in inflammatory bowel disease Cancer 56 12 1985 2914 2921
41. S.L. Masel, and S.B. Hanauer Increased association of lymphoma and inflammatory bowel disease Gastroenterology 118 4 2000 119
42. S.H. Mir-Madjlessi, R.G. Farmer, K.A. Easley, and G.J. Beck Colorectal and extracolonic malignancy in ulcerative colitis Cancer 58 7 1986 1569 1574
43. L. Mellemkjaer, C. Johansen, G. Gridley, M.S. Linet, S.K. Kjaer, and J.H. Olsen Crohn's disease and cancer risk (Denmark) Cancer Causes Control 11 2 2000 145 150
44. K.O. Arseneau, G.J. Stukenborg, A.F. Connors Jr., and F. Cominelli The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients Inflamm Bowel Dis 7 2 2001 106 112
45. L.J. Kinlen, A.G. Sheil, J. Peto, and R. Doll Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs Br Med J 2 6203 1979 1461 1466
46. W.R. Connell, M.A. Kamm, M. Dickson, A.M. Balkwill, J.K. Ritchie, and J.E. Lennard-Jones Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease Lancet 343 8908 1994 1249 1252
47. B.I. Korelitz, F.J. Mirsky, M.R. Fleisher, J.I. Warman, N. Wisch, and G.W. Gleim Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine Am J Gastroenterol 94 11 1999 3248 3253
48. D.H. Present, S.J. Meltzer, M.P. Krumholz, A. Wolke, and B.I. Korelitz 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity Ann Intern Med 111 8 1989 641 649
49. K.D. Glazier, A.L. Palance, L.H. Griffel, and K.M. Das The 10-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease J Clin Gastroenterol 39 1 2005 21 26
50. A.E. Kandiel, A.J. Fraser, B.I. Korelitz, C.M. Brensinger, and J.D. Lewis Azathioprine and 6-mercaptopurine use for inflammatory bowel disease is associated with an increased risk of lymphoma Gastroenterology 126 4 2004 19
51. J.D. Lewis, J.S. Schwartz, and G.R. Lichtenstein Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma Gastroenterology 118 6 2000 1018 1024
52. P. Lewis, B.L. Hazleman, R. Hanka, and S. Roberts Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine Ann Rheum Dis 39 5 1980 457 461
53. P. Prior, D.P. Symmons, C.F. Hawkins, D.L. Scott, and R. Brown Cancer morbidity in rheumatoid arthritis Ann Rheum Dis 43 2 1984 128 131
54. M.A. Nalesnik, R. Jaffe, and T.E. Starzl The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression Am J Pathol 133 1 1988 173 192
55. D.W. Hanto, G. Frizzera, and D.T. Purtilo Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus Cancer Res 41 11 Pt 1 1981 4253 4261
56. O.W. Kamel, M. van de Rijn, and L.M. Weiss Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis N Engl J Med 328 18 1993 1317 1321
57. T.M. Dawson, G. Starkebaum, B.L. Wood, R.F. Willkens, and A.M. Gown Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjogren's syndrome: case series J Rheumatol 28 1 2001 47 53
58. L. Larvol, J.C. Soule, and A. Le Tourneau Reversible lymphoma in the setting of azathioprine therapy for Crohn's disease N Engl J Med 331 13 1994 883 884
59. S. Li, and M.J. Borowitz Primary Epstein-Barr virus-associated Hodgkin disease of the ileum complicating Crohn disease Arch Pathol Lab Med 125 3 2001 424 427
60. S. Kumar, F. Fend, and L. Quintanilla-Martinez Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression Am J Surg Pathol 24 1 2000 66 73
61. M.R. Calaminici, M.T. Sheaff, A.J. Norton, and R.M. Feakins Ileocaecal Epstein-Barr virus-positive lymphoproliferative disorder complicating Crohn's disease Histopathology 35 4 1999 388 390
62. G.A. Dayharsh, E.V. Loftus Jr., and W.J. Sandborn Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine Gastroenterology 122 1 2002 72 77
63. A.J. Wakefield, J.D. Fox, and A.M. Sawyerr Detection of herpesvirus DNA in the large intestine of patients with ulcerative colitis and Crohn's disease using the nested polymerase chain reaction J Med Virol 38 3 1992 183 190
64. P. Munkholm, E. Langholz, M. Davidsen, and V. Binder Intestinal cancer risk and mortality in patients with Crohn's disease Gastroenterology 105 6 1993 1716 1723
65. N.A. Wong, and D.J. Harrison Colorectal neoplasia in ulcerative colitis-recent advances Histopathology 39 3 2001 221 234
66. F. Wolfe, and K. Michaud Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients Arthritis Rheum 50 6 2004 1740 1751
67. I. Penn Cancers following cyclosporin therapy Transplantation 43 1987 32 35
68. W.J. Sandborn Optimizing anti-tumor necrosis factor strategies in inflammatory bowel disease Curr Gastroenterol Rep 5 6 2003 501 505
69. W.J. Sandborn, B.G. Feagan, and S.B. Hanauer An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial Gastroenterology 120 6 2001 1330 1338
70. W.J. Sandborn, S.B. Hanauer, and S. Katz Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 5 2001 1088 1094
71. P. Rutgeerts, G. D'Haens, and S. Targan Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 4 1999 761 769
72. J.F. Colombel, E.V. Loftus Jr., and W.J. Tremaine The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients Gastroenterology 126 1 2004 19 31
73. S.J. Bickston, G.R. Lichtenstein, K.O. Arseneau, R.B. Cohen, and F. Cominelli The relationship between infliximab treatment and lymphoma in Crohn's disease Gastroenterology 117 6 1999 1433 1437
74. S.L. Brown, M.H. Greene, S.K. Gershon, E.T. Edwards, and M.M. Braun Tumor necrosis factor antagonist therapy and lymphoma development: 26 cases reported to the Food and Drug Administration Arthritis Rheum 46 12 2002 3151 3158
75. FDA Board Document. Update on the TNF-alpha blocking agents; 2003 [available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm ].
76. G.R. Lichtenstein, R.D. Cohen, and B.G. Feagan Safety of infliximab in Crohn's disease: data from the 5000-patient TREAT registry Gastroenterology 126 4 2004 54
77. T. Ljung, P. Karlen, and D. Schmidt Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County Gut 53 6 2004 849 853
78. M.C. Stephens, M.A. Shepanski, P. Mamula, J.E. Markowitz, K.A. Brown, and R.N. Baldassano Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center Am J Gastroenterol 98 2003 104 111
79. S. Ardizzone, E. Colombo, G. Maconi, G. Manzionna, M. Petrone, and G. Bianchi Porro Infliximab in treatment of Crohn's disease: the Milan experience Dig Liver Dis 34 2002 411 418
80. R.J. Farrell, S.A. Shah, and P.J. Lodhavia Clinical experience with infliximab therapy in 100 patients with Crohn's disease Am J Gastroenterol 95 2000 3490 3497
81. J. Seiderer, B. Goke, and T. Ochsenkuhn Safety aspects of infliximab in inflammatory bowel disease patients Digestion 70 2004 3 9
82. H.H. Wenzl, W. Reinisch, and J. Jahnel Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up Eur J Gastrenterol Hepatology 16 2003 767 773